Royal Bank of Canada Grows Position in Healthpeak Properties, Inc. $DOC

Posted by George Bondi on Aug 4th, 2026

Royal Bank of Canada raised its stake in Healthpeak Properties, Inc. (NYSE:DOC – Free Report) by 18.4% in the 1st quarter, Holdings Channel reports. The institutional investor owned 1,909,419 shares of the real estate investment trust’s stock after buying an additional 296,556 shares during the period. Royal Bank of Canada’s holdings in Healthpeak Properties were worth $31,372,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. New York Life Investment Management LLC grew its holdings in shares of Healthpeak Properties by 65.8% during the 4th quarter. New York Life Investment Management LLC now owns 156,086 shares of the real estate investment trust’s stock worth $2,510,000 after purchasing an additional 61,952 shares during the period. Oak Thistle LLC acquired a new stake in shares of Healthpeak Properties during the fourth quarter valued at about $3,938,000. Baillie Gifford & Co. raised its stake in shares of Healthpeak Properties by 613.2% in the 4th quarter. Baillie Gifford & Co. now owns 367,256 shares of the real estate investment trust’s stock valued at $5,905,000 after acquiring an additional 315,763 shares during the period. Swedbank AB raised its stake in shares of Healthpeak Properties by 433.4% in the 4th quarter. Swedbank AB now owns 849,215 shares of the real estate investment trust’s stock valued at $13,655,000 after acquiring an additional 690,000 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Healthpeak Properties by 176.0% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 320,040 shares of the real estate investment trust’s stock worth $5,146,000 after acquiring an additional 204,100 shares during the last quarter. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Healthpeak Properties Trading Down 0.7%

Shares of DOC stock opened at $21.68 on Tuesday. Healthpeak Properties, Inc. has a fifty-two week low of $15.70 and a fifty-two week high of $22.95. The company has a 50 day moving average price of $21.05 and a 200 day moving average price of $18.70. The stock has a market capitalization of $14.95 billion, a P/E ratio of 67.77, a price-to-earnings-growth ratio of 3.39 and a beta of 1.02. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.96 and a current ratio of 2.96.

Healthpeak Properties (NYSE:DOC – Get Free Report) last released its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The company had revenue of $752.95 million for the quarter, compared to analyst estimates of $694.59 million. During the same period in the prior year, the business earned $0.46 EPS. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. Equities research analysts predict that Healthpeak Properties, Inc. will post 1.75 EPS for the current fiscal year.

Healthpeak Properties Announces Dividend

The business also recently disclosed a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be given a dividend of $0.1017 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a c) dividend on an annualized basis and a dividend yield of 5.6%. Healthpeak Properties’s dividend payout ratio is currently 381.25%.

Wall Street Analyst Weigh In

DOC has been the subject of a number of research analyst reports. BMO Capital Markets increased their price objective on shares of Healthpeak Properties from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Citigroup upped their price target on Healthpeak Properties from $17.50 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $22.00 price objective (up from $20.00) on shares of Healthpeak Properties in a report on Thursday, June 11th. Finally, Evercore lowered Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price on the stock. in a research note on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.62.

Get Our Latest Stock Report on DOC

Insider Activity

In other news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total value of $213,736.05. Following the sale, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.

Healthpeak Properties Profile

(Free Report)

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.